Materials used in the presented study are: carvedilol (CARV, Ph. Eur. 9.0) and following (co)polymers: polyvinylpyrrolidone(PVP, Kollidon ® 30, BASF, Germany), hydroxypropyl methylcellulose (HPMC, Methocel ® E5 LV, Dow ® , USA), polyvinyl acetate and polyvinyl caprolactam copolymer (Soluplus ® , BASF, Germany) and poly-(N-dimethylaminoethyl methacrylateco-methyl methacrylate-co-butyl methacrylate (Eudragit ® E-100, Evonik, Germany). Commercial carbon dioxide (purity 99%) was supplied by Messer-Tehnogas (Serbia).
Methocel e5 lv
Manufactured by Dow
Sourced in United States
Methocel® E5 LV is a methylcellulose-based product manufactured by Dow. It is a water-soluble polymer that can be used as a thickening, suspending, and binding agent in various applications.
Automatically generated - may contain errors
Lab products found in correlation
Soluplus, by BASF (1 mentions)
Eudragit e100, by Evonik (1 mentions)
Kollidon 30, by BASF (1 mentions)
Orthophosphoric acid, by Merck Group (1 mentions)
Milli q purification system, by Merck Group (1 mentions)
Acetonitrile, by Merck Group (1 mentions)
Gentiopicroside, by ChromaDex (1 mentions)
Ethocel standard 20 premium, by Dow (1 mentions)
4 protocols using methocel e5 lv
1
Carvedilol Formulation Development
2
Gentiopicroside Formulation and Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Excipients used for formulation were hydroxypropyl methylcellulose (HPMC, Methocel ® E5 LV, Dow ® , USA), hydrophilic polymer used as a matrix forming excipient, lactose monohydrate was used as a diluent, citric acid and sodium bicarbonate as an effervescent components, while glyceryl behenate (Compritol ® 888 ATO, Gattefrosse, Saint-Priest, Cedex, France) and stearoyl macrogol-32 glycerides (Gelucire ® 50/13, Gattefrosse, Saint-Priest, Cedex, France) were used as meltable binders. Ethanol 96 % (v/v) (Honeywell Riedel de Haën, Seelze, Germany), orthophosphoric acid (Sigma-Aldrich Chemie GmbH, Münich, Germany), acetonitrile (Merck, Germany) was HPLC grade and ultra-pure water was prepared using a Milli-Q purification system (Millipore, France). Gentiopicroside (ChromaDex, USA) standard was used. All excipients, reagents and standards used were of analytical grade.
3
Barrier Membrane Coating for HCTZ Tablets
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Matrix tablets of HCTZ were coated with an insoluble barrier membrane (BM) using aqueous ethylcellulose coating, Surelease® (containing medium chain triglyceride as plasticizer) and an HPMC-based Opadry® (HPMC low viscosity grade, 6 cps, triacetin, and talc) as a pore former, at 85:15 and 60:40 w/w ratios. The ratio of Surelease to Opadry was calculated based on total dry solids. Prior to application, the coating systems were dispersed in water at 10% w/w solids content. Tablets (batch size, 1 kg) were then coated to 2%–8% w/w weight gain (WG) in a fully perforated coating pan (LABCOAT I, O’Hara Technologies, Canada) using a 1-mm nozzle (970/7-1S75, Schlick, Germany). Standard coating processing parameters were used for application of aqueous ethylcellulose barrier membrane coating (i.e., product temperature, 42°C–45°C; spray rate of 6–8 g/min; air flow of 290 m3/h).
It is generally known that organic application of ethylcellulose coating can result in stronger film compared to the aqueous system. For comparison, the HCTZ matrix tablet cores containing lactose were also coated using a combination of ethylcellulose (ETHOCEL™ Standard 20 Premium) and hypromellose (METHOCEL E5LV) (The Dow Chemical Company, USA), as a pore former, at 85:15 and 60:40 w/w in a solvent mixture of isopropanol and water, 90:10 w/w, at 7% solids content.
It is generally known that organic application of ethylcellulose coating can result in stronger film compared to the aqueous system. For comparison, the HCTZ matrix tablet cores containing lactose were also coated using a combination of ethylcellulose (ETHOCEL™ Standard 20 Premium) and hypromellose (METHOCEL E5LV) (The Dow Chemical Company, USA), as a pore former, at 85:15 and 60:40 w/w in a solvent mixture of isopropanol and water, 90:10 w/w, at 7% solids content.
4
Pharmaceutical Tablet Formulation Development
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Met (Weifa) was passed through a 1.0 mm screen and then mixed with one of the following binders: vinylpyrrolidone–vinyl acetate copolymer (Kollidon VA64 fine: VA64, BASF), polyvidone (Povidone K12: PVP, BASF), hydroxypropyl cellulose (HPC SSL SF: HPC, Nippon Soda), and hydroxypropyl methylcellulose (Methocel E5 LV: HPMC, Dow Chemical). Batch scales of 250 g were processed in a high shear granulator (Diosna P1/6, Diosna) equipped with a 1 L granulation bowl. Processing parameters were kept constant throughout the agglomeration (1 min) and massing (3 min) stage: impeller 500 rpm, chopper 1200 rpm. The mixtures were granulated by spraying 1.0%, 1.5%, or 2.0% (m/m) water for about 10–15 s (nozzle diameter 0.3 mm, atomizing air pressure 2.5 bar) into the granulation bowl. The pre-sieved lubricant magnesium stearate (vegetable magnesium stearate, Faci) was blended directly into the granulator for 0.5 min at a reduced impeller speed of 250 rpm. The final blends were sieved by a conical sieving machine (1.0 mm rasp sieve, Quadro Comil U5, Powrex).
The final blends were compressed to flat-faced tablets with a diameter of 8 mm and mass of 200 mg on an eccentric press (FlexiTab, Manesty) at different compression stages of 2.5 kN, 5 kN, 7.5 kN, 10.0 kN, and 15.0 kN.
The final blends were compressed to flat-faced tablets with a diameter of 8 mm and mass of 200 mg on an eccentric press (FlexiTab, Manesty) at different compression stages of 2.5 kN, 5 kN, 7.5 kN, 10.0 kN, and 15.0 kN.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!